An interventional study of Platelet-rich fibrin and Control group in Fibrin/Therapeutic Use, Blood Platelets and Molar, Third, sponsored by Rio de Janeiro State University. Completed at 1 site in Brazil. Open to participants aged 16 Years to 29 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-12.
Sponsored by Rio de Janeiro State University · Not applicable, Interventional, and Treatment
The purpose of this study is to evaluate the bone regeneration after impacted third molar surgery on split mouth design using platelet-rich fibrin.
195 studies on the registry are indexed under Tooth, Impacted; 20 are open to participants now.
This study's enrollment of 20 is below the median of 53 across 164 interventional studies indexed under Tooth, Impacted.
Browse Tooth, Impacted studies →Rio de Janeiro State University is the lead sponsor of 62 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Use platelet-rich fibrin after mandibular third molar extraction
Procedure: Platelet-rich fibrin
mandibular third molar extraction
Procedure: Control group
Change in bone density through tomography evaluation
Time frame: Change from Baseline bone measurement at three months after surgery
Change in periodontal-probing depth measurement on distal aspect of the second molar through Clinical evaluation
Time frame: Change from baseline at 3 months after surgery
Pain through Visual Analogue Scale
Time frame: 1st day after surgery
Pain through Visual Analogue Scale
Time frame: 3rd day after surgery
Pain through Visual Analogue Scale
Time frame: 7th day after surgery
Soft tissue healing through Clinical evaluation numeric scale
Time frame: 7th day after surgery
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rio de Janeiro State University